U F Power

Summary

Affiliation: Centre de Recherche Pierre Fabre
Country: France

Publications

  1. ncbi Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein
    U F Power
    Centre d Immunologie Pierre Fabre, 74164 Cedex, Saint Julien en Genevois, France
    Vaccine 19:2345-51. 2001
  2. ncbi Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults
    U F Power
    Centre d Immunologie Pierre Fabre, Saint Julien en Genevois, France
    J Infect Dis 184:1456-60. 2001
  3. ncbi Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice
    U F Power
    Centre d Immunologie Pierre Fabre, 74164 Saint Julien en Genevois, France
    J Virol 75:12421-30. 2001
  4. ncbi The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B
    Ultan F Power
    Centre d Immunologie Pierre Fabre, 74164, Saint Julien en Genevois, France
    Vaccine 22:168-76. 2003
  5. ncbi Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein
    H Plotnicky-Gilquin
    Centre d Immunologie Pierre Fabre, 74164 Saint Julien en Genevois cedex, France
    J Virol 73:5637-45. 1999
  6. ncbi CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment
    H Plotnicky-Gilquin
    Centre d Immunologie Pierre Fabre, 74 164 St Julien en Genevois, France
    J Virol 74:3455-63. 2000
  7. ncbi A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine
    N Dagouassat
    , Centre d'Immunologie Pierre-Fabre, , BP 497, F74164, Saint-Julien-en-Genevois, France
    Vaccine 19:4143-52. 2001
  8. ncbi Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G
    M Sugawara
    Institut de Pharmacologie et de Biologie Structurale--Centre National de la Recherche Scientifique, Toulouse, France
    J Pept Res 60:271-82. 2002

Collaborators

Detail Information

Publications8

  1. ncbi Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein
    U F Power
    Centre d Immunologie Pierre Fabre, 74164 Cedex, Saint Julien en Genevois, France
    Vaccine 19:2345-51. 2001
    ..However, all the identified murine B cell protectopes were conserved in RSV seropositive humans. Should these protectopes correspond with protection in humans, BBG2Na may constitute a very interesting vaccine candidate against RSV...
  2. ncbi Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults
    U F Power
    Centre d Immunologie Pierre Fabre, Saint Julien en Genevois, France
    J Infect Dis 184:1456-60. 2001
    ..Antibody responses to 2 murine lung protective epitopes were also highly boosted after vaccination. Therefore, BBG2Na is safe, well tolerated, and highly immunogenic in RSV-seropositive adults...
  3. ncbi Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice
    U F Power
    Centre d Immunologie Pierre Fabre, 74164 Saint Julien en Genevois, France
    J Virol 75:12421-30. 2001
    ..Consequently, our data suggest that BBG2Na may constitute a safe RSV subunit vaccine for use in seronegative infants...
  4. ncbi The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B
    Ultan F Power
    Centre d Immunologie Pierre Fabre, 74164, Saint Julien en Genevois, France
    Vaccine 22:168-76. 2003
    ..However, the duration of protective immunity will probably be insufficient to prevent RSV-B infection for the duration of the RSV epidemic season...
  5. ncbi Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein
    H Plotnicky-Gilquin
    Centre d Immunologie Pierre Fabre, 74164 Saint Julien en Genevois cedex, France
    J Virol 73:5637-45. 1999
    ..Should these murine protectopes also be implicated in human LRT protection, their clustering around the highly conserved cysteine noose region will have important implications for the development of RSV vaccines...
  6. ncbi CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment
    H Plotnicky-Gilquin
    Centre d Immunologie Pierre Fabre, 74 164 St Julien en Genevois, France
    J Virol 74:3455-63. 2000
    ..Taken together, these results demonstrate for the first time that CD4(+) T cells induced upon parenteral immunization with an RSV G protein fragment play a critical role in URT protection of normal mice against RSV infection...
  7. ncbi A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine
    N Dagouassat
    , Centre d'Immunologie Pierre-Fabre, , BP 497, F74164, Saint-Julien-en-Genevois, France
    Vaccine 19:4143-52. 2001
    ..From a physicochemical point of view, this unique property of BBG2Na makes it eminently suitable for combination to either paediatric or elderly multivalent AH- or AP-containing vaccines already in the market or in development...
  8. ncbi Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G
    M Sugawara
    Institut de Pharmacologie et de Biologie Structurale--Centre National de la Recherche Scientifique, Toulouse, France
    J Pept Res 60:271-82. 2002
    ....